Anxiety disorders are a prevalent and disabling condition. Because of high rates of treatment resistance, there is interest in new pharmacological treatment options such as second-generation antipsychotics. This systematic review evaluated the efficacy and tolerability of second-generation antipsychotics in the treatment of anxiety disorders. We found eleven randomised placebo-controlled trials, comparing quetiapine, olanzapine and risperidone with placebo and antidepressants. The vast majority of the available data was on quetiapine (> 3000 participants). Participants with generalised anxiety disorder responded significantly better to quetiapine than to placebo, measured as a reduction in the Hamilton Anxiety Scale (HAM-A). Participants treated with quetiapine were more likely to drop out due to adverse events, to gain weight, to suffer from sedation or to suffer from extrapyramidal side effects. The evidence on the other second-generation antipsychotics is currently too limited to draw any conclusions.
- Association of weekend continuity of care with hospital length of stay
- Referendums, Opinion Polls, and Public Relations: The Australian Gallup Poll and the 1951 Referendum on Communism
- Development of a diabetes prevention program for Surinamese South Asians in the Netherlands
- Health literacy, self-perceived health and self-reported chronic morbidity among older people in Kosovo
- Using a public health approach to improve end-of-life care: results and discussion of a health needs assessment undertaken in a large city in northern England
Category Specific RSS